Phaseline

Companies › Olema Pharmaceuticals

Olema Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Palazestrant (OP-1250)
Complete Estrogen Receptor Antagonist
ESR1Phase 3Breast Cancer; Metastatic Breast CancerDec 2027
OP-3136
Selective inhibitor of KAT6A and KAT6B
KAT6A, KAT6BPhase 1Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05266105Palazestrant (OP-1250)Phase 1Breast CancerOncologyMar 2026
NCT06784193OP-3136Phase 1Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)OncologyMay 2027
NCT05508906Palazestrant (OP-1250)Phase 1Metastatic Breast CancerOncologyDec 2027
NCT06016738Palazestrant (OP-1250)Phase 3Breast CancerOncologyFeb 2028
NCT07085767Palazestrant (OP-1250)Phase 3Breast CancerOncologyDec 2028

From the company's SEC filings

Cash and short-term investments of $414m on 2026-09-30; operating cash outflow about $187m a year; runway about 27 months at that burn, to Dec 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

KAT6A (1) KAT6B (1) ESR1 (1)

Companies with the same targets

Pfizer BeOne Medicines AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics

Companies built like this

Stemline Therapeutics ORIC Pharmaceuticals Shanghai Best-Link Bioscience ArriVent BioPharma Cogent Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.